Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

References

• Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020;579(7798):265–269.
   PubMed Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.
   PubMed Web of Science ®Google Scholar
• Tang JW, Tambyah PA, Hui DS. Emergence of a new SARS-CoV-2 variant in the UK. J Infect. 2020;S0163-4453(20): 30786–6.
   Google Scholar
• Volz E, Hill V, Mccrone JT, et al. Evaluating the effects of SARS-CoV-2 spike mutation D614G on transmissibility and pathogenicity. Cell. 2021;184(1):64–75.
   PubMed Web of Science ®Google Scholar
• Evans C. Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus. Cell. 2020;182(4):812–827.
   PubMed Web of Science ®Google Scholar
• Rambaut A, Loman N, Pybus O, et al. Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations 2020 [ cited 2021 Feb 15]. Available from: https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563
   Google Scholar
• Tegally H, Wilkinson E, Giovanetti M, et al. Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa. Nature. 2021.DOI:10.1038/s41586-021-03402-9.
   Google Scholar
• Faria NR, Claro IM, Candido D, et al. Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings 2021 [cited 2021 Feb 15]. Available from: https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586
   Google Scholar
• PANGO lineages. B.1.1.7 report 2021 [cited 2021 Feb 15]. Available from: https://cov-lineages.org/global_report_B.1.1.7.html
   Google Scholar
• Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: insights from linking epidemiological and genetic data. medRxiv. 2021. DOI:10.1101/2020.12.30.20249034.
   PubMedGoogle Scholar
• PANGO lineages. B.1.351 report 2021 [cited 2021 Feb 15]. Available from: https://cov-lineages.org/global_report_B.1.351.html
   Google Scholar
• PANGO lineages. P.1 report 2021 [cited 2021 Feb 15]. Available from: https://cov-lineages.org/global_report_P.1.html
   Google Scholar
• CGTN. Guangdong detects first COVID-19 case of variant found in S. Africa 2021 [cited 2021 Feb 15]. Available from: https://news.cgtn.com/news/2021-01-06/Guangdong-detects-first-COVID-19-case-of-variant-found-in-S-Africa-WPW5sbHcju/index.html
   Google Scholar
• Chen H, Huang X, Zhao X. et al. Notes from the field: the first case of new variant COVID-19 originating in the United Kingdom detected in a returning student — shanghai Municipality, China, December 14, 2020. China CDC Weekly. 2021;3(1):1–3.
   Google Scholar
• Piccoli L, Park Y-J, Tortorici MA, et al. Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology. Cell. 2020;183(4):1024–1042.e21.
   PubMed Web of Science ®Google Scholar
• McCallum M, Marco AD, Lempp F, et al. N-terminal domain antigenic mapping reveals a site of vulnerability for sars-cov-2. bioRxiv. 2021. DOI:10.1101/2021.01.14.426475
   Google Scholar
• Cerutti G, Guo Y, Zhou T, et al. Potent sars-cov-2 neutralizing antibodies directed against spike n-terminal domain target a single supersite. bioRxiv. 2021. DOI:10.1101/2021.01.10.426120
   Google Scholar
• Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature. 2020;588(7839):682–687.
   PubMed Web of Science ®Google Scholar
• Cele S, Gazy I, Jackson L, et al. Escape of SARS-CoV-2 501Y.V2 variants from neutralization by convalescent plasma. Public Health. 2021. DOI:10.1101/2021.01.26.21250224
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. bioRxiv. 2021. DOI:10.1038/s41586-021-03398-2.
   Google Scholar
• Garcia-Beltran WF, Lam EC, Denis KS, et al. Circulating SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity. medRxiv. 2021. DOI:10.1101/2021.02.14.21251704
   Google Scholar
• Hou YJ, Chiba S, Halfmann P, et al. SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo. Science. 2020;370(6523):1464–1468.
   PubMed Web of Science ®Google Scholar
• Daniloski Z, Jordan TX, Ilmain JK, et al. The Spike D614G mutation increases SARS-CoV-2 infection of multiple human cell types. eLife. 2021;10. DOI:10.7554/eLife.65365
   PubMed Web of Science ®Google Scholar
• Ozono S, Zhang Y, Ode H, et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat Commun. 2021;12(1):1.
   PubMed Web of Science ®Google Scholar
• Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature. 2020. DOI:10.1038/s41586-020-2895-3
   PubMed Web of Science ®Google Scholar
• Di Teodoro G, Valleriani F, Puglia I, et al. SARS-CoV-2 replicates in respiratory ex vivo organ cultures of domestic ruminant species. Vet Microbiol. 2021;252:108933.
   PubMed Web of Science ®Google Scholar
• Lorenzo-Redondo R, Nam HH, Roberts SC, et al. A unique clade of SARS-CoV-2 viruses is associated with lower viral loads in patient upper airways. medRxiv. 2020. DOI:10.1101/2020.05.19.20107144
   PubMedGoogle Scholar
• Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059.
   PubMed Web of Science ®Google Scholar
• Weissman D, Alameh M-G, De Silva T, et al. D614G spike mutation increases SARS CoV-2 susceptibility to neutralization. Cell Host Microbe. 2021;29(1):23–31.e4.
   PubMed Web of Science ®Google Scholar
• Thomson EC, Rosen LE, Shepherd JG, et al. Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity. Cell. 2021;184(5):1171–1187.e20.
   Web of Science ®Google Scholar
• Public Health England. Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01. 2020.  [cited 2021 Feb 15]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959360/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3.pdf
   Google Scholar
• O’Toole A, Hill V, Pybus OG, et al. Tracking the international spread of SARS-CoV-2 lineages B.1.1.7 and B.1.351/501Y-V2 2021 [cited 2021 Mar 6]. Available from: https://virological.org/t/tracking-the-international-spread-of-sars-cov-2-lineages-b-1-1-7-and-b-1-351-501y-v2/592
   Google Scholar
• Wang P, Nair MS, Liu L, et al. Increased resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 to antibody neutralization. bioRxiv. 2021. DOI:10.1101/2021.01.25.428137
   Google Scholar
• Bal A, Destras G, Gaymard A, et al. Two-step strategy for the identification of SARS-CoV-2 variant of concern 202012/01 and other variants with spike deletion H69–V70, France, August to December 2020. Eurosurveillance. 2021;26(3):3.
   Google Scholar
• Group NaERVTA. Meeting on SARS-CoV-2 variant under investigation VUI-202012/01. 2020 [cited 2021 Feb 15]. Available from: https://khub.net/documents/135939561/338928724/SARS-CoV-2±variant±under±investigation%2C±meeting±minutes.pdf/962e866b-161f-2fd5-1030-32b6ab467896?t=1608470511452
   Google Scholar
• Shen X, Tang H, Mcdanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing antibodies elicited by ancestral spike vaccines. Social Science Electronic Publishing; 2021. Available from:https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3777473
   Google Scholar
• Collier DA, Marco AD, Ferreira IATM, et al. Impact of SARS-CoV-2 B.1.1.7 spike variant on neutralisation potency of sera from individuals vaccinated with Pfizer vaccine BNT162b2. medRxiv. 2021. DOI:10.1101/2021.01.19.21249840
   Google Scholar
• Muik A, Wallisch A-K, Sänger B, et al. Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera. Science. 2021;371(6534):eabg6105.
   Web of Science ®Google Scholar
• Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. Virology. 2021. DOI:10.1101/2021.01.10.426120
   Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2020;29(1):44–57.
   PubMed Web of Science ®Google Scholar
• Baum A, Fulton BO, Wloga E, et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science. 2020;369(6506):1014–1018.
   PubMed Web of Science ®Google Scholar
• Greaney AJ, Starr TN, Gilchuk P, et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe. 2021;29(1):44–57.e9.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zheng H, Lin H, et al. Identification of common deletions in the spike protein of severe acute respiratory syndrome coronavirus 2. J Virol. 2020;94(17):17.
   Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. eLife. 2020;9. DOI:10.7554/eLife.61312
   PubMed Web of Science ®Google Scholar
• Wibmer CK, Ayres F, Hermanus T, et al. SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma. Nat Med. 2021. DOI:10.1101/2021.01.18.427166
   Web of Science ®Google Scholar
• Johnson & Johnson. Johnson & Johnson announces single-shot Janssen COVID-19 vaccine candidate met primary endpoints in interim analysis of its Phase 3 ENSEMBLE trial 2021 [cited 2021 Feb 15]. Available from: https://www.jnj.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints-in-interim-analysis-of-its-phase-3-ensemble-trial
   Google Scholar
• Witwatersrand U Oxford Covid-19 vaccine trial results 2021 [cited 2021 Feb 15]. Available from: https://www.wits.ac.za/covid19/covid19-news/latest/oxford-covid-19-vaccine-trial-results.html
   Google Scholar
• Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial 2021 [cited 2021 Feb 15]. Available from: https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-893-efficacy-uk-phase-3
   Google Scholar
• Vaccine KK 2.0: moderna and other companies plan tweaks that would protect against new coronavirus mutations 2021 [cited 2021 Feb 15]. Available from: https://www.sciencemag.org/news/2021/01/vaccine-20-moderna-and-other-companies-plan-tweaks-would-protect-against-new
   Google Scholar
• PANGO lineages. A.23.1 report 2021 [cited 2021 Feb 15]. Available from: https://cov-lineages.org/global_report_A.23.1.html
   Google Scholar
• PANGO lineages. B.1.525 report 2021 [cited 2021 Feb 15]. Available from: https://cov-lineages.org/global_report_B.1.525.html
   Google Scholar
• Lule BD, Phan MVT, Ssewanyana I, et al. A SARS-CoV-2 lineage A variant (A.23.1) with altered spike has emerged and is dominating the current Uganda epidemic. medRxiv. 2021. DOI:10.1101/2021.02.08.21251393
   Google Scholar
• Zhang W, Davis BD, Chen SS, et al. Emergence of a novel SARS-CoV-2 variant in southern California. JAMA. 2021. DOI:10.1101/2021.01.18.21249786
   Web of Science ®Google Scholar
• Jones BE, Brown-Augsburger PL, Corbett KS, et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv. 2020. DOI:10.1101/2020.09.30.318972
   Google Scholar
• Andreano E, Piccini G, Licastro D, et al. SARS-CoV-2 escape in vitro from a highly neutralizing COVID-19 convalescent plasma. bioRxiv. 2020. DOI:10.1101/2020.12.28.424451
   PubMedGoogle Scholar
• Supasa P, Zhou D, Dejnirattisai W, et al. Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine sera. Cell. 2021. DOI:10.1016/j.cell.2021.02.033
   Web of Science ®Google Scholar
• Zhou D, Dejnirattisai W, Supasa P, et al. Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine induced sera. Cell. 2021. DOI:10.1016/j.cell.2021.02.037
   PubMed Web of Science ®Google Scholar
• Jangra S, Ye C, Rathnasinghe R, et al. The E484K mutation in the SARS-CoV-2 spike protein reduces but does not abolish neutralizing activity of human convalescent and post-vaccination sera. medRxiv. 2021. DOI:10.1101/2021.01.26.21250543
   Google Scholar
• Rathnasinghe R, Jangra S, Cupic A, et al. The N501Y mutation in SARS-CoV-2 spike leads to morbidity in obese and aged mice and is neutralized by convalescent and post-vaccination human sera. medRxiv. 2021. DOI:10.1101/2021.01.19.21249592
   Google Scholar
• Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021. DOI:10.1038/s41591-021-01270-4
   Web of Science ®Google Scholar
• Xie X, Zou J, Fontes-Garfias CR, et al. Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera. bioRxiv. 2021. DOI:10.1101/2021.01.07.425740
   Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv. 2021. DOI:10.1101/2021.01.25.427948
   Google Scholar
• Huang B, Dai L, Wang H, et al. Neutralization of SARS-CoV-2 VOC 501Y.V2 by human antisera elicited by both inactivated BBIBP-CorV and recombinant dimeric RBD ZF2001 vaccines. bioRxiv. 2021. DOI:10.1101/2021.02.01.429069.
   Google Scholar
• Oxford University. Oxford vaccine effective against major B.1.1.7 ‘Kent’ coronavirus strain circulating in the UK 2021 [cited 2021 Feb 15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-05-oxford-vaccine-effective-against-major-b-1-1-7-kent-coronavirus-strain-circulating-in-the-uk
   Google Scholar
• Oxford University. ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young South African adults 2021 [cited 2021 Feb 15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-07-chadox1-ncov-19-minimal-protection-against-mild-covid-19-from-b-1-351-variant-in-young-sa-adults
   Google Scholar
• Janet Woodcock MD Coronavirus (COVID-19) Update: FDA continues important work to support medical product development to address new virus variants 2021 [cited 2021 Feb 15]. Available from: https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-continues-important-work-support-medical-product-development-address
   Google Scholar
• CNN. Moderna expects vaccine will be protective against variants, but will test boosters to improve immunity. 2021 [cited 2021 Feb 15]. Available from: https://www.wktv.com/content/news/573657962.html
   Google Scholar
• Sputnik. The Russian direct investment fund is willing to start combined clinical trials of the Sputnik V and AstraZeneca vaccine in Ukraine 2021 [cited 2021 Feb 15]. Available from: http://sputniknews.cn/covid-2019/202101031032825830/
   Google Scholar
• Oxford University. Oxford leads first trial investigating dosing with alternating vaccines 2021 [cited 2021 Feb 15]. Available from: https://www.research.ox.ac.uk/Article/2021-02-04-oxford-leads-first-trial-investigating-dosing-with-alternating-vaccines
   Google Scholar
• Public Health England. COVID-19 vaccination programme Information for healthcare practitioners 2021 [cited 2021 Feb 15]; Version 3.3 [ Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/960977/COVID-19_vaccination_programme_guidance_for_healthcare_workers_11_February_2021_v3.3.pdf
   Google Scholar
• Stephen M, Hahn MD. FDA Statement on Following the Authorized Dosing Schedules for COVID-19 Vaccines 2021 [cited 2021 Feb 15]. Available from: https://www.fda.gov/news-events/press-announcements/fda-statement-following-authorized-dosing-schedules-covid-19-vaccines
   Google Scholar
• Businesswire. Moderna COVID-19 Vaccine Retains Neutralizing Activity Against Emerging Variants First Identified in the U.K. and the Republic of South Africa 2021 [cited 2021 Feb 15]. Available from: https://www.businesswire.com/news/home/20210125005439/en
   Google Scholar
• GlaxoSmithKline. GSK and CureVac to develop next generation mRNA COVID-19 vaccines 2021 [cited 2021 Feb 15]. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-and-curevac-to-develop-next-generation-mrna-covid-19-vaccines/
   Google Scholar